{
  "nctId": "NCT06958614",
  "briefTitle": "Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC",
  "officialTitle": "Efficacy and Safety of Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor During Definitive Concurrent Chemoradiotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer: A Prospective Cohort Study",
  "protocolDocument": {
    "nctId": "NCT06958614",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-06-23",
    "uploadDate": "2025-04-25T01:38",
    "size": 608153,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06958614/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 213,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-09-02",
    "completionDate": "2025-01-30",
    "primaryCompletionDate": "2024-11-07",
    "firstSubmitDate": "2025-03-28",
    "firstPostDate": "2025-05-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Diagnosis\n\n   * Histologically confirmed stage II-III non-small cell lung cancer (NSCLC)\n2. Treatment Plan\n\n   * Planned to receive concurrent platinum-based chemotherapy with radiotherapy (cCRT)\n3. Demographics\n\n   * Age 18-80 years\n4. Performance Status\n\n   * Karnofsky Performance Status (KPS) ≥70\n5. Organ Function\n\n   * Renal function: Creatinine clearance ≥60 mL/min\n   * Hepatic function: Total bilirubin ≤1.5×ULN, AST/ALT ≤2.5×ULN\n   * Absolute neutrophil count ≥2.0×10⁹/L\n   * Platelets ≥100×10⁹/L\n   * Hemoglobin ≥10 g/dL\n\nExclusion Criteria:\n\n1. Active Malignancies\n\n   * Concurrent diagnosis of active malignancies (excluding: non-melanoma skin cancer, carcinoma in situ, or malignancies in complete remission for ≥5 years)\n2. Infectious/Immunological Conditions\n\n   * Active systemic infection requiring intravenous antimicrobial therapy\n   * Uncontrolled autoimmune diseases (defined as requiring systemic immunosuppressants at doses \\>10 mg/day prednisone equivalent within 30 days prior to screening)\n3. Hypersensitivity Reactions\n\n   * Allergy to PEG-rhG-CSF or other biological products derived from genetically engineered Escherichia coli\n4. Neuropsychiatric Impairments\n\n   * Severe psychiatric disorders (e.g., schizophrenia, major depressive disorder with suicidal ideation) requiring hospitalization within 6 months)\n5. Prior Radiotherapy\n\n   * History of thoracic radiotherapy involving \\>30% lung parenchyma or mean heart dose \\>20 Gy",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Grade 3 or more (G3+) neutropenia",
        "description": "According to the Radiation Therapy Oncology Group (RTOG) acute radiation injury grading scale",
        "timeFrame": "From the first day of radiotherapy to one month after the end of radiotherapy"
      }
    ],
    "secondary": [
      {
        "measure": "treatment delays",
        "description": "Chemotherapy delay",
        "timeFrame": "Chemotherapy delay was defined as a delay of ≥7 days"
      },
      {
        "measure": "interruptions",
        "description": "Radiotherapy interruption",
        "timeFrame": "Break in radiotherapy of ≥3 days"
      },
      {
        "measure": "G3+ thrombocytopenia and anemia",
        "description": "According to the Radiation Therapy Oncology Group (RTOG) acute radiation injury grading scale",
        "timeFrame": "From the first day of radiotherapy to one month after the end of radiotherapy"
      },
      {
        "measure": "G2+ acute radiation esophagitis (RE) and pneumonitis (RP)",
        "description": "According to the Radiation Therapy Oncology Group (RTOG) acute radiation injury grading scale",
        "timeFrame": "From the first day of radiotherapy to six month after the end of radiotherapy"
      },
      {
        "measure": "progression-free survival (PFS)",
        "description": "the time from the start of cCRT to the first event of disease progression",
        "timeFrame": "assessed up to 72 months"
      },
      {
        "measure": "overall survival (OS)",
        "description": "the time from the start of cCRT to death from any cause",
        "timeFrame": "assessed up to 72 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 59,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:50.273Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}